Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic approaches for antigen-selective cell therapy.

L Alvarez-Vallina1

  • 1Department of Immunology, Hospital Universitario Clínica Puerta de Hierro, San Martín de Porres, 4, 28035 Madrid, Spain. lalvarezv@hpth.insalud.es

Current Gene Therapy
|July 12, 2002
PubMed
Summary

Innovative adoptive T-cell therapies engineer immune cells to target cancer and viral infections. Chimeric immune receptors (CIRs) and biespecic antibody fragments offer new strategies for potent, long-term systemic immunity against diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.

European journal of cancer (Oxford, England : 1990)·2019
Same author

A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.

Scientific reports·2019
Same author

Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.

Gene therapy·2017
Same author

The axonal repellent Slit2 inhibits pericyte migration: potential implications in angiogenesis.

Experimental cell research·2011
Same author

Non-hematopoietic stem cells as factories for in vivo therapeutic protein production.

Gene therapy·2011
Same author

Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system.

Gene therapy·2010

Area of Science:

  • Immunology
  • Cell Therapy
  • Molecular Biology

Background:

  • Adoptive T-cell therapies aim to enhance immune responses against diseases.
  • Current strategies seek to combine antibody specificity with immune cell effector functions.
  • Antigen-selective cell therapies are being developed for MHC- and cytokine-independent T-cell activation.

Purpose of the Study:

  • To review innovative strategies in adoptive T-cell therapy, focusing on antigen-selective approaches.
  • To discuss the development and potential of chimeric immune receptors (CIRs) and biespecic antibody-mediated immune recruitment (BIR).
  • To explore the transition from effector cell-based to progenitor cell-based therapies for sustained immunity.

Main Methods:

  • Genetic manipulation of T-cells to express chimeric immune receptors (CIRs) with antibody specificity.

Related Experiment Videos

  • Utilizing biespecic antibody fragments for trans-recruitment and multieffector activation.
  • Evaluating both in vitro and in vivo model systems for therapeutic efficacy.

    • Main Results:

    • CIR-expressing cells demonstrate specific stimulation and antigen-bearing cell killing.
    • Progenitor cell-based therapies can generate long-term persistent systemic immunity.
    • Biespecic antibody-mediated immune recruitment (BIR) approaches show promise in complementing CIR therapies.

    Conclusions:

    • Antigen-selective cell therapies, including CIR and BIR, represent significant advancements in cell-mediated immunotherapy.
    • Further research is needed to optimize effector cell selection and targeting strategies.
    • Ongoing clinical trials will determine the efficacy of these novel immunotherapies in cancer and HIV patients.